Venus Medtech (Hangzhou) Inc.
VMTHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.00 | -0.03 | -0.38 |
| FCF Yield | -51.62% | -2,600.69% | -18.12% | -4.50% |
| EV / EBITDA | -0.17 | -0.16 | -4.04 | -32.37 |
| Quality | ||||
| ROIC | -11.40% | -14.26% | -12.53% | -5.57% |
| Gross Margin | 78.11% | 79.21% | 77.25% | 77.99% |
| Cash Conversion Ratio | -0.03 | 0.87 | 0.85 | 1.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.02% | 5.72% | 13.77% | 21.25% |
| Free Cash Flow Growth | 97.96% | 3.89% | -50.85% | -66.76% |
| Safety | ||||
| Net Debt / EBITDA | -0.12 | -0.09 | 0.98 | 8.90 |
| Interest Coverage | -20.82 | -9.41 | -14.57 | -146.27 |
| Efficiency | ||||
| Inventory Turnover | 1.05 | 0.90 | 0.89 | 1.01 |
| Cash Conversion Cycle | 496.86 | 498.41 | 648.52 | 591.26 |